Vela Diagnostics Launches HCV Genotyping Next-Generation Sequencing Assay

Singapore (January 20, 2015) – Vela Diagnostics announced today the launch of the Sentosa® SQ Hepatitis C Virus (HCV) Genotyping Next-Generation Sequencing (NGS) Assay, the first assay of its NGS virology portfolio. The Sentosa® SQ HCV Genotyping NGS Assay is available for Research Use Only.

The Sentosa® SQ HCV Genotyping Assay detects genotypes 1, 2, 3, 4, 5 and 6, and subtypes 1a and 1b by targeting NS3, NS5A and NS5B regions; it exhibits a Limit of Detection (LOD) of 1000 IU/mL for genotypes 1a, 1b, 2, 3 and 4, and 2000 IU/mL for genotypes 5 and 6.

The Sentosa® SQ HCV Genotyping Assay is designed for use on the automated Sentosa® NGS workflow that consists of the Sentosa® SX101 automated pipetting system enabling automated RNA extraction and library set-up, and the NGS system. The NGS system comprises the Sentosa® ST401 instruments for automated template preparation, the Sentosa® SQ301 sequencer and server, as well as the Sentosa® SQ Reporter for efficient data analysis and report generation.

The automated Sentosa® NGS workflow offers computerized reporting and enables rapid and accurate genotyping across the complex HCV genome, hence increasing efficiency and reducing costs. The easy-to-interpret report format includes automated bioinformatics and results interpretation. The Sentosa® NGS workflow also promotes seamless sample tracking and network connectivity to ease information transfer and sample traceability.

Vela Diagnostics offers automated platforms that support both NGS and PCR workflows. The workflows share the Sentosa® SX101 automated pipetting system thereby increasing efficiency and flexibility. Three additional NGS panels are planned for 2015. 

Go back